{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T07:10:09Z","timestamp":1758957009231,"version":"3.44.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12185-025-04016-x","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:29:03Z","timestamp":1749853743000},"page":"616-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review"],"prefix":"10.1007","volume":"122","author":[{"given":"Yayoi","family":"Ueda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-7768","authenticated-orcid":false,"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuji","family":"Mino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Hayashino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"4016_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"4016_CR2","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2147\/CMAR.S287922","volume":"13","author":"J Xu","year":"2021","unstructured":"Xu J, Wang M, Shen Y, Yan M, Xie W, Wang B, et al. Effects of amyloid light-chain amyloidosis on clinical characteristics and prognosis in multiple myeloma: a single-center retrospective study. Cancer Manag Res. 2021;13:1343\u201356.","journal-title":"Cancer Manag Res"},{"key":"4016_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"4016_CR4","doi-asserted-by":"publisher","first-page":"e003783","DOI":"10.1136\/jitc-2021-003783","volume":"9","author":"A Oliver-Caldes","year":"2021","unstructured":"Oliver-Caldes A, Jimenez R, Espanol-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, et al. First report of CART treatment in AL amyloidosis and relapsed\/refractory multiple myeloma. J Immunother Cancer. 2021;9:e003783.","journal-title":"J Immunother Cancer"},{"key":"4016_CR5","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-22-0637","volume":"28","author":"S Kfir-Erenfeld","year":"2022","unstructured":"Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, et al. Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis. Clin Cancer Res. 2022;28:5156\u201366.","journal-title":"Clin Cancer Res"},{"key":"4016_CR6","doi-asserted-by":"publisher","first-page":"9627","DOI":"10.3390\/curroncol30110697","volume":"30","author":"S Das","year":"2023","unstructured":"Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo RD. Anti-B cell maturation antigen chimeric antigen receptor T cell therapy for the treatment of AL amyloidosis and concurrent relapsed\/refractory multiple myeloma: preliminary efficacy and safety. Curr Oncol. 2023;30:9627\u201333.","journal-title":"Curr Oncol"},{"key":"4016_CR7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/ejh.14293","volume":"113","author":"U Goel","year":"2024","unstructured":"Goel U, Dima D, Davis J, Ahmed N, Shaikh H, Lochner J, et al. Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma and concurrent light chain amyloidosis. Eur J Haematol. 2024;113:817\u201323.","journal-title":"Eur J Haematol"},{"key":"4016_CR8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ehf2.14554","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang K, Suo X, Meng N, Gu Y, Qin Y, et al. B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma. ESC Heart Fail. 2024;11:574\u201380.","journal-title":"ESC Heart Fail"},{"key":"4016_CR9","doi-asserted-by":"crossref","unstructured":"Lebel E, Asherie N, Kfir-Erenfeld S, Grisariu S, Avni B, Elias S, et al. Efficacy and safety of anti-B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis. J Clin Oncol. 2024:JCO2402252.","DOI":"10.26226\/m.65f9bf89e6f73964e1d4ea83"},{"key":"4016_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612\u20135.","journal-title":"Blood"},{"key":"4016_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4016_CR12","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer. 2022; 10.","DOI":"10.1136\/jitc-2021-004475"},{"key":"4016_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"4016_CR14","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139.","journal-title":"J Clin Oncol"},{"key":"4016_CR15","first-page":"220","volume":"109","author":"S Oubari","year":"2024","unstructured":"Oubari S, Hegenbart U, Schoder R, Steinhardt M, Papathanasiou M, Rassaf T, et al. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica. 2024;109:220\u201330.","journal-title":"Haematologica"},{"key":"4016_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood.2023022937","volume":"143","author":"N Forgeard","year":"2024","unstructured":"Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, et al. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series. Blood. 2024;143:734\u20137.","journal-title":"Blood"},{"key":"4016_CR17","doi-asserted-by":"crossref","unstructured":"Jamroziak K, Zielonka K, Khwaja J, Wechalekar AD. Update on B-cell maturation antigen-directed therapies in AL amyloidosis. Br J Haematol. 2025.","DOI":"10.1111\/bjh.19960"},{"key":"4016_CR18","doi-asserted-by":"crossref","unstructured":"Liang X, Wang Y, Luo B, Lin B, Lu W, Tian S, et al. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. J Immunother Cancer. 2024; 12.","DOI":"10.1136\/jitc-2024-010064"},{"key":"4016_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39:543\u201354.","journal-title":"Leukemia"},{"key":"4016_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","volume":"30","author":"LD Anderson Jr","year":"2024","unstructured":"Anderson LD Jr, Dhakal B, Jain T, Oluwole OO, Shah GL, Sidana S, et al. Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the american society for transplantation and cellular therapy. Transplant Cell Ther. 2024;30:17\u201337.","journal-title":"Transplant Cell Ther"},{"key":"4016_CR21","doi-asserted-by":"crossref","unstructured":"Staron A, Mendelson LM, Joshi T, Burke N, Sanchorawala V. Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis. Br J Haematol. 2024.","DOI":"10.1111\/bjh.19766"},{"key":"4016_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-020-0306-5","volume":"10","author":"S Sidana","year":"2020","unstructured":"Sidana S, Milani P, Binder M, Basset M, Tandon N, Foli A, et al. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J. 2020;10:41.","journal-title":"Blood Cancer J"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04016-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T06:52:09Z","timestamp":1758955929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04016-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4016"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04016-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YM received research funding from Bristol-Myers Squibb Company and Astellas Pharma Inc., and honoraria from Bristol-Myers Squibb Company, Mundipharma Co. Ltd., and Kyowa Kirin Co. Ltd. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board at Okayama University Hospital (#2023016).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patient and his family.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}